Regulation of CD47 expression in cancer cells

被引：74

作者：

Huang, Can-Yu ^{[1
]}

Ye, Zi-Han ^{[1
]}

Huang, Mu-Yang ^{[1
]}

Lu, Jin-Jian ^{[1
]}

机构：

[1] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, 5005a,N22,Ave Univ, Taipa, Macao, Peoples R China

来源：

TRANSLATIONAL ONCOLOGY | 2020年 / 13卷 / 12期

关键词：

CD47; Cytokine; Oncogene; MicroRNA; QPCTL; INTEGRIN-ASSOCIATED PROTEIN; HUMAN GLUTAMINYL CYCLASE; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; B7-H1; EXPRESSION; TARGETING CD47; UP-REGULATION; STEM-CELLS; SIRP-ALPHA;

D O I：

10.1016/j.tranon.2020.100862

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CD47 is overexpressed in various types of cancers and it can directly bind with SIRP alpha, which is mainly located on macrophages. The binding of CD47-SIRP alpha transmits a "don't eat me" signal, which can prevent cancer cells from immune clearance. Targeting the phagocytosis checkpoint of CD47-SIRP alpha axis has shown remarkable anticancer effect in preclinical and clinical research, which indicates the potential application of CD47-SIRP alpha blockade for cancer treatment. In this case, the comprehensive description of the regulation of CD47 in different types of cancer cells has significant implications for furthering our understanding of the role of CD47 in cancer. Based on the current reports, we summarized the regulatory factors, i.e., cytokines, oncogenes, microRNAs as well as enzymes, of CD47 expression in cancer cells. Accordingly, we also proposed several points needing further research, hoping to provide useful insights for the future investigation on the regulation of CD47 in cancers.

引用

页数：7

共 96 条

[61] Non-coding RNAs as drug targets [J].

Matsui, Masayuki ;

Corey, David R. .

NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (03) :167-179

[62]

Meng Z., 2019, TJC4 DIFFERENTIATED

[63]

Moon JY, 2017, SCI REP, V7, P1

[64]

Nabors LLB, 2003, CANCER RES, V63, P4181

[65] Role of CD47 as a marker of self on red blood cells [J].

Oldenborg, PA ;

Zheleznyak, A ;

Fang, YF ;

Lagenaur, CF ;

Gresham, HD ;

Lindberg, FP .

SCIENCE, 2000, 288 (5473) :2051-+

[66] Antitumour actions of interferons: implications for cancer therapy [J].

Parker, Belinda S. ;

Rautela, Jai ;

Hertzog, Paul J. .

NATURE REVIEWS CANCER, 2016, 16 (03) :131-144

[67] Mechanisms of type-I- and type-II-interferon-mediated signalling [J].

Platanias, LC .

NATURE REVIEWS IMMUNOLOGY, 2005, 5 (05) :375-386

[68] Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation [J].

Quandt, Dagmar ;

Jasinski-Bergner, Simon ;

Mueller, Ulrike ;

Schulze, Bianca ;

Seliger, Barbara .

JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12

[69] Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma [J].

Rastgoo, Nasrin ;

Wu, Jian ;

Liu, Aijun ;

Pourabdollah, Maryam ;

Atenafu, Eshetu G. ;

Reece, Donna ;

Chen, Wenming ;

Chang, Hong .

HAEMATOLOGICA, 2020, 105 (12) :2813-2823

[70] Costimulation of T cell activation by integrin-associated protein (CD47) is an adhesion-dependent, CD28-independent signaling pathway [J].

Reinhold, MI ;

Lindberg, FP ;

Kersh, GJ ;

Allen, PM ;

Brown, EJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (01) :1-11

← 1 2 3 4 5 6 7 8 9 10 →